The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization
Open accessAbstract
Objective—: Lipoprotein(a)-hyperlipoproteinemia (Lp(a)-HLP) along with progressive cardiovascular disease has been approved as indication for regular lipoprotein apheresis (LA) in Germany since 2008. We aimed to study the long-term preventive effect of LA and to assess hypothetical clinical correlations of apolipoprotein(a) (apo(a)) by analyzing genotypes and phenotypes. Approach and Results—: This prospective observational multicenter study included 170 patients with Lp(a)-HLP and progressive cardiovascular disease (48.9 years median age at diagnosis) despite other cardiovascular risk factors, including low-density lipoprotein cholesterol had maximally been treated (mean baseline low-density lipoprotein cholesterol: measured, 2.56 mmol/L [98.9 mg/dL] and corrected, 1.72 mmol/L [66.3 mg/dL]). Patients were prospectively investigated during a 5-year period about annual incidence rates of cardiovascular events. In addition, apo(a) isoforms and polymorphisms at the apo(a) gene ( LPA ) were characterized. One hundred fifty-four patients (90.6%) completed 5 years of follow-up. Mean Lp(a) concentration before commencing regular LA was 108.1 mg/dL. This was reduced by a single LA treatment by 68.1% on average. Significant decline of the mean annual cardiovascular event rate was observed from 0.58±0.53 2 years before regular LA to 0.11±0.15 thereafter ( P <0.0001); 95.3% of patients expressed at least 1 small apo(a) isoform. Small apo(a) isoform (35.2%) carrying phenotypes were not tagged by single-nucleotide polymorphisms rs10455872 or rs3798220. Conclusions—: Results of 5 years of prospective follow-up confirm that LA has a lasting effect on prevention of cardiovascular events in patients with Lp(a)-HLP. Patients clinically selected by progressive cardiovascular disease were characterized by a highly frequent expression of small apo(a) isoforms. Only Lp(a) concentration seemed to comprehensively reflect Lp(a)-associated cardiovascular risk, however.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Two studies reported a significantly lower cardiovascular event rate in patients treated with lipid apheresis for Lp(a) [194, 195].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [195]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipoprotein(a) as a cardiovascular risk factor: current status
Nordestgaard, B. G., Chapman, M. J., Ray, K., Borén, J., Andreotti, F., Watts, G. F., Ginsberg, H., Amarenco, P., Catapano, A., Descamps, O. S., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq386 · Cited by 1,807
Self-citationGenetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902604 · Cited by 1,671
Genetically Elevated Lipoprotein(a) and Increased Risk of Myocardial Infarction
Kamstrup, P. R. (2009) · JAMA · doi:10.1001/jama.2009.801 · Cited by 1,357 · cited 1×
“These are all translated and lead to a size polymorphism of apo(a), which is causally associated with Lp(a) concentrations in an inverse manner.(4,5) Lp(a) isoforms have been categorized as small (≤22 KIV repeats) or large (>22 KIV repeats) with small isoforms, implying an ≈2-fold higher risk of CVD.”
BackgroundSelf-citationMechanisms of Acute Coronary Syndromes and Their Implications for Therapy
Libby, P. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1216063 · Cited by 1,262
Single LDL Apheresis Improves Endothelium-Dependent Vasodilatation in Hypercholesterolemic Humans
Tamai, O., Matsuoka, H., Itabe, H., Wada, Y., Kohno, K., & Imaizumi, T. (1997) · Circulation · doi:10.1161/01.cir.95.1.76 · Cited by 543
Lipoprotein(a): resurrected by genetics
Kronenberg, F., & Utermann, G. (2013) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2012.02592.x · Cited by 521
Self-citationTsimikas, S., Viney, N. J., Hughes, S. G., Singleton, W., Graham, M. J., Baker, B. F., Burkey, J. L., Yang, Q., Marcovina, S. M., Geary, R. S., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61252-1 · Cited by 460
Lipoprotein (a) measurements for clinical application
Marcovina, S. M., & Albers, J. J. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r061648 · Cited by 338
Apolipoprotein(a) Isoforms and the Risk of Vascular Disease
Erqou, S. A., Thompson, A., Angelantonio, E. D., Saleheen, D., Kaptoge, S., Marcovina, S. M., & Danesh, J. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.10.080 · Cited by 330
Leebmann, J., Roeseler, E., Julius, U., Heigl, F., Spitthöver, R., Heutling, D., Breitenberger, P., Maerz, W., Lehmacher, W., Heibges, A., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.002432 · Cited by 329
Self-citationRole of Lipoprotein(a) and Apolipoprotein(a) Phenotype in Atherogenesis
Kronenberg, F., Kronenberg, M. F., Kiechl, S. J., Trenkwalder, E., Santer, P., Oberhollenzer, F., Egger, G., Utermann, G., & Willeit, J. (1999) · Circulation · doi:10.1161/01.cir.100.11.1154 · Cited by 292
Self-citationRecommendations for the use of LDL apheresis
Thompson, G. R. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.02.009 · Cited by 270
Kraft, H. G., K�chl, S., Menzel, H., Sandholzer, C., & Utermann, G. (1992) · Human Genetics · doi:10.1007/bf00220066 · Cited by 270
Kronenberg, F., Kuen, E., Ritz, E., Junker, R., Diaeresis]NIG, P. K., KRAATZ, G. D., Lhotta, K., Mann, J. F. E., DiaeresisLLER, G. A. M., Neyer, U., et al. (2000) · Journal of the American Society of Nephrology · doi:10.1681/asn.v111105 · Cited by 246
Self-citationKamstrup, P. R., & Nordestgaard, B. G. (2016) · JACC: Heart Failure · doi:10.1016/j.jchf.2015.08.006 · Cited by 206 · cited 1×
“These are all translated and lead to a size polymorphism of apo(a), which is causally associated with Lp(a) concentrations in an inverse manner.(4,5) Lp(a) isoforms have been categorized as small (≤22 KIV repeats) or large (>22 KIV repeats) with small isoforms, implying an ≈2-fold higher risk of CVD.”
BackgroundSelf-citationDesai, N. R., Kohli, P., Giugliano, R. P., O’Donoghue, M. L., Somaratne, R. M., Zhou, J., Hoffman, E. B., Huang, F., Rogers, W. J., Wasserman, S. M., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.001969 · Cited by 179
Yeang (2015) · doi:10.1097/mol.0000000000000171 · Cited by 152
Tsimikas, S., Clopton, P., Brilakis, E. S., Marcovina, S. M., Khera, A., Miller, E. R., de Lemos, J. A., & Witztum, J. L. (2009) · Circulation · doi:10.1161/circulationaha.108.836940 · Cited by 151
Laschkolnig, A., Kollerits, B., Lamina, C., Meisinger, C., Rantner, B., Stadler, M., Peters, A., Köenig, W., Stockl, A., Dahnhardt, D., et al. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu107 · Cited by 146
Self-citationEfficacy criteria and cholesterol targets for LDL apheresis
Thompson, G. R., Barbir, M., Davies, D., Dobral, P., Gesinde, M., Livingston, M., Mandry, P., Marais, A. D., Matthews, S. B., Neuwirth, C. K. Y., et al. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.06.010 · Cited by 135
Impairment of Endothelium-Dependent Dilation in Rabbit Renal Arteries by Oxidized Lipoprotein(a)
Galle, J., Bengen, J., Schollmeyer, P. J., & Wanner, C. (1995) · Circulation · doi:10.1161/01.cir.92.6.1582 · Cited by 133
Wu, H. D., Berglund, L., Dimayuga, C. A., Jones, J. A., Sciacca, R. R., Tullio, M. R. D., & Homma, S. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.08.066 · Cited by 72
Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia
Arai, K., Orsoni, A., Mallat, Z., Tedgui, A., Witztum, J. L., Bruckert, É., Tselepis, A. D., Chapman, M. J., & Tsimikas, S. (2012) · Journal of Lipid Research · doi:10.1194/jlr.p027235 · Cited by 67
Kronenberg, F., Lingenhel, A., Lhotta, K., Rantner, B., Kronenberg, M. F., König, P., Thiery, J., Koch, M., von Eckardstein, A., & Dieplinger, H. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00737.x · Cited by 62
Self-citationHeigl, F., Hettich, R., Lotz, N., Reeg, H., Pflederer, T., OSTERKORN, D., Osterkorn, K., & Klingel, R. (2015) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2015.02.013 · Cited by 61
Self-citationLipoprotein(a) mass: A massively misunderstood metric
McConnell, J. P., Guadagno, P. A., Dayspring, T. D., Hoefner, D. M., Thiselton, D. L., Warnick, G. R., & Harris, W. S. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.08.003 · Cited by 52
Noureen, A., Fresser, F., Utermann, G., & Schmidt, K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121582 · Cited by 51
Self-citationKronenberg, F. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12207 · Cited by 27
Self-citationDittrich-Riediger, J., Schatz, U., Hohenstein, B., & Julius, U. (2015) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2015.02.007 · Cited by 24
Self-citationGrimm, J. M., Nikolaou, K., Schindler, A., Hettich, R., Heigl, F., Cyran, C. C., Schwarz, F., Klingel, R., Karpinska, A., Yuan, C., et al. (2012) · Journal of Cardiovascular Magnetic Resonance · doi:10.1186/1532-429x-14-80 · Cited by 21
Self-citationShiffman, D., Slawsky, K. A., Fusfeld, L., Devlin, J. J., & Goss, T. F. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.04.004 · Cited by 16
Schatz, U., Illigens, B. M. W., Siepmann, T., Arneth, B. M., Siegert, G., Siegels, D., Heigl, F., Hettich, R., Ramlow, W., Prophet, H., et al. (2015) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2015.02.030 · Cited by 6
Self-citationBarbero (2014) · doi:10.1016/j · Cited by 1
Cited by
Sorted by citations
Padmanabhan, A., Connelly‐Smith, L. S., Aqui, N. A., Balogun, R. A., Klingel, R., Meyer, E., Pham, H. P., Schneiderman, J., Witt, V., Wu, Y., et al. (2019) · Journal of Clinical Apheresis · doi:10.1002/jca.21705 · Cited by 2,260
Self-citationA Test in Context: Lipoprotein(a)
Tsimikas, S. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.042 · Cited by 1,137
“When apheresis has been performed to lower Lp(a), a reduction in cardiovascular risk has been suggested (63,64).”
BackgroundReyes-Soffer, G., Ginsberg, H. N., Berglund, L., Duell, P. B., Heffron, S. P., Kamstrup, P. R., Lloyd-Jones, D. M., Marcovina, S. M., Yeang, C., Koschinsky, M. L., et al. (2022) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000147 · Cited by 836
Self-citationConnelly‐Smith, L. S., Alquist, C. R., Aqui, N. A., Hofmann, J. C., Klingel, R., Onwuemene, O. A., Patriquin, C. J., Pham, H. P., Sanchez, A. P., Schneiderman, J., et al. (2023) · Journal of Clinical Apheresis · doi:10.1002/jca.22043 · Cited by 751
Self-citationEffect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
Bittner, V. A., Szarek, M., Aylward, P. E., Bhatt, D. L., Diaz, R., Edelberg, J. M., Fras, Z., Goodman, S. G., Halvorsen, S., Hanotin, C., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.10.057 · Cited by 572
Metadata
- Authors
- Roeseler, E., Julius, U., Heigl, F., Spitthoever, R., Heutling, D., Breitenberger, P., Leebmann, J., Lehmacher, W., Kamstrup, P. R., Nordestgaard, B. G., Maerz, W., Noureen, A., Schmidt, K., Kronenberg, F., Heibges, A., Klingel, R., Schettler, V., Benzing, T., Christ, H., Wehner, S., Schulz-Merkel, I., Kuehn, R., Wagner, A., Dschietzig, W., Ernst, C., Koziolek, M., Bunia, J., Kulzer, P., Kraenzle, K.-D., Toelle, M., Riechers, G., Kuehnel, C., Marsen, T., Saehn, C., Ringel, J., Messner, H., Oehring, A., Schuerfeld, C., Wintergalen, M., Schettler, V., Neumann, F., Kaul, H., Haesner, M., Passfall, J., Benschneider, A., Heidenreich, S., März, W., Klaes, R., Binner, P., Dieplinger, H., Erhart, G., Fassbender, C., & Christ, H.
- Affiliations
- Technische Universität Dresden (DE)
- From the Center for Nephrology, Hypertension, and Metabolic Diseases, Hannover, Germany (E.R.); 3rd Medical Clinic, University Hospital at the Technische Universität, Dresden, Germany (U.J.); Medical Health and Care Center Kempten-Allgäu, Kempten, Germany (F.H.); Dialysis and Lipid Center North Rhine, Essen, Germany (R.S.); Clinic for Nephrology and Dialysis, Tangermuende, Germany (D.H.); KfH-Kidney Center, Germering, Germany (P.B.); 1st Medical Clinic, General Hospital, Passau, Germany (J.L.);...
- Cologne
- Hannover
- Kempten
- Tangermuende
- Trier
- Cottbus
- Goettingen
- Iserlohn
- Marktheidenfeld
- Memmingen
- Berlin
- Braunschweig
- Krefeld
- Potsdam
- Wuppertal
- Suhl
- Saarlouis
- Olpe
- Dresden
- Deggendorf
- Aachen
- Mannheim
- Innsbruck, Austria
- ORCID
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2016-09
- Volume
- 36
- Issue
- 9
- Pages
- 2019-2027
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2556080334
- Semantic Scholar
- 012bba31547ed986fa3a0e3d76102f0991dd9ee5
- Cited by
- 227
- References
- 32
- Citations by year
- 2026: 18 · 2025: 15 · 2024: 21 · 2023: 32 · 2022: 20 · 2021: 20 · 2020: 16 · 2019: 36 · 2018: 16 · 2017: 30 · 2016: 2
- FWCI
- 30.97
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Arteriosclerosis Thrombosis and Vascular Biology (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Keywords
- lipoprotein apheresis, apolipoprotein(a), cardiovascular disease prevention, cardiovascular events, apolipoprotein(a) isoforms, rs10455872, rs3798220, cardiovascular risk, LDL cholesterol
- MeSH terms
- Aged, Blood Component Removal, Cardiovascular Diseases, Female, Follow-Up Studies, Germany, Humans, Hyperlipoproteinemias, Male, Middle Aged, Phenotype, Prospective Studies, Risk Factors, Time Factors, Biomarkers, Incidence, Treatment Outcome, Lipoprotein(a), Risk Assessment, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, Apoprotein(a)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
